SCHEMBL4740233

SCHEMBL4740233

CC#CC(CC(=O)OC)c1ccc(OCc2cccc(-c3ccc(C(F)(F)F)cc3)c2)cc1

nearest known ligand 0.83

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 20/20 0.83
▸ GNA15 P30679 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521232 1.00 FFAR1 (0.83) FFAR1GNA15
SCHEMBL13318253 1.00 FFAR1 (0.83) FFAR1GNA15
SCHEMBL12191648 0.91 FFAR1 (0.86) FFAR1GNA15
SCHEMBL13118205 0.91 FFAR1 (1.00) FFAR1GNA15
SCHEMBL3553422 0.91 FFAR1 (1.00) FFAR1GNA15
SCHEMBL12194429 0.91 FFAR1 (1.00) FFAR1GNA15
SCHEMBL29367214 0.91 FFAR1 (1.00) FFAR1GNA15
SCHEMBL3518942 0.90 FFAR1 (0.98) FFAR1GNA15
SCHEMBL3518944 0.90 FFAR1 (0.84) FFAR1GNA15
SCHEMBL5297901 0.90 FFAR1 (0.98) FFAR1GNA15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893582-B1 Compounds, their pharmaceutical compositions and their use in treating metabolic disorders AMGEN INC (US) 2011-12-14 — — EP disclosed
EP-1893582-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2008-03-05 — — EP disclosed
EP-1737809-A4 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2007-10-17 — — EP disclosed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 — — EP disclosed
WO-2006127503-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2006-11-30 — — WO disclosed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 — — WO disclosed
Send feedback